

Open Peer Review on Qeios

Tumor Antigen-reactive CD28+/CCR7+/CD27+/CD45RA- Cytotoxic T-lymphocyte

National Cancer Institute

Source

National Cancer Institute. <u>Tumor Antigen-reactive CD28+/CCR7+/CD27+/CD45RA-Cytotoxic T-lymphocyte</u>. NCI Thesaurus. Code C118848.

A subset of rapidly expanding, tumor antigen-reactive central memory cytotoxic T-lymphocytes (CTLs) with a broad expression profile for markers of immune function (MIF), and a particular phenotype of CD28+/CCR7+/CD27+/CD45RA-. These CTLs are formed in vivo following administration of AGS-003 (an autologous, CD40L and tumor antigen RNA-transfected dendritic cell (DC) immunotherapeutic agent), secrete multiple cytokines, including interferon-gamma (IFN-g), tumor necrosis factor-alpha (TNF-a), and interleukin-2 (IL-2), and cause cell lysis. These antigen-reactive, CD28+/CCR7+/CD27+/CD45RA- CTLs, and the phenotype changes in the patient's peripheral blood CTL pool, can be used as a marker to evaluate a patient's immune response against the administered immunotherapeutic agent AGS-003.

Qeios ID: 5EXF3Y · https://doi.org/10.32388/5EXF3Y